Patients commonly reported unexplained blurred or hazy vision postoperatively that requires further investigation ...

Vyznova is under clinical development by Aurion Biotechnologies and currently in Phase II for Corneal Edema. According to GlobalData, Phase II drugs for Corneal Edema does not have sufficient ...

auckland.ac.nz Background/aims To analyse the clinical and microstructural changes during the course of acute corneal hydrops in keratoconus. Methods A prospective study of consecutive patients ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

The Latest The CLARA Phase 1/2, prospective, multi-center, randomized, double-masked, parallel-arm dose-ranging clinical trial designed to assess the safety, tolerability and efficacy of AURN001 for ...

In May 2023, results of a phase 2 study of 49 subjects with corneal edema were presented, showing faster visual recovery in the active treatment group (Baartman et al). Cells may be derived from ...

EyeYon Medical is proud to announce its expansion in China with the establishment of a new subsidiary, Zhuhai EyeYon Medical ...

gmail.com Aim Detailed longitudinal evaluation of corneal and other ophthalmological features of patients with lipoid proteinosis (LP). Methods Ophthalmological examinations, chart review, ultrasound ...